| Literature DB >> 35201652 |
Ryo Kurokawa1, Akira Baba1, Pinarbasi Emile2, Mariko Kurokawa1, Yoshiaki Ota1, John Kim1, Aristides Capizzano1, Ashok Srinivasan1, Toshio Moritani1.
Abstract
BACKGROUND ANDEntities:
Keywords: angiocentric glioma; magnetic resonance imaging; systematic review
Mesh:
Year: 2022 PMID: 35201652 PMCID: PMC9306893 DOI: 10.1111/jon.12983
Source DB: PubMed Journal: J Neuroimaging ISSN: 1051-2284 Impact factor: 2.324
FIGURE 1Flow diagram of study identification. SCOPUS is Elsevier's abstract and citation database. n, number
Demographic, clinical, and imaging data of the 3 patients with angiocentric gliomas in our hospital
| Demographic & clinical data | Patient | 1 | 2 | 3 | |
| Age at diagnosis (years) | 2 | 43 | 10 | ||
| Sex | Male | Male | Male | ||
| Seizure/epilepsy | No | Yes | Yes | ||
| Seizure/epilepsy started (years) | 8 | 10 | |||
| Surgery | No (biopsy‐proven) | Yes | Yes | ||
| Chemotherapy | Yes | No | No | ||
| Recurrence, period (from surgery) | No | No | |||
| Patient status | Survive | Survive | Survive | ||
| Follow up duration (month) | 39 | 72 | 38 | ||
| Imaging data | Size (mm: Anteroposterior × transverse × craniocaudal) | 38 × 40 × 41 | 8 × 9 × 10 | 24 × 28 × 21 | |
| Laterality | Middle | Left | Left | ||
| Tumor site | Pons, Medulla | Frontal lobe | Occipital lobe | ||
| Tumor margin | Well | Well | Well | ||
| Involvement of both cortex and subcortex | Yes | Yes | |||
| Massive surrounding edema (≥tumor size) | No | No | No | ||
| Morphology | Solid | Cystoid | Solid | ||
| MRI signal intensity | T2‐weighted image (compared with cortex) | High | High | High | |
| Fluid‐attenuated inversion recovery image (compared with cortex) | High | High & Low | High | ||
| T1‐weighted image (compared with cortex) | Low | High & Low | Low | ||
| Apparent diffusion coefficient (10–3mm2/s) | 1.6 | 1.04 | 1.34 | ||
| Stalk‐like sign | No | Yes | Yes | ||
| Atrophy of the brain parenchyma near the tumor site | No | Yes | No | ||
| Contrast enhancement | No | No | Nodular |
Demographic and clinical information of the 50 patients with angiocentric gliomas
| Demographic | |
|---|---|
| Median age at diagnosis (years [range]) | 13 [2‐83] |
| Sex | Male = 35, Female = 14, Not described = 1 |
| Clinical | |
| Seizure/epilepsy | 36/50 (72.0%) |
| Median length of seizure/epilepsy history (years [range])a | 2 [<1‐35] |
| Treatment strategy | |
| Surgery alone | 39/48 (81.3%) |
| Surgery and radiation | 1/48 (2.1%) |
| Surgery and chemotherapy | 2/48 (4.2%) |
| Chemotherapy alone | 3/48 (6.3%) |
| Chemotherapy and radiation | 1/48 (2.1%) |
| Follow‐up | 1/48 (2.1%) |
| Recurrence after complete resection | 2/29 (6.9%) |
| Patient status | Survive = 40/41 (97.6%), Death = 1/41 (2.4%) |
| Follow‐up duration (median [range]) (41 patients) | 16 months [2‐84] |
The length was calculated by subtracting the age of seizure/epilepsy onset from age at diagnosis. The length of the patients presenting with their first episode of seizure/epilepsy was calculated as zero (6 cases). Cases without a specific history length were excluded from the calculation (7 cases).
Neuroimaging characteristics of the 50 patients with angiocentric gliomas
| Parameters | ||
|---|---|---|
| Size (median [range]) (21 tumors)a | 26 mm [10‐70] | |
| Laterality | ||
| Right | 14/50 (28.0%) | |
| Left | 28/50 (56.0%) | |
| Middle | 7/50 (14.0%) | |
| Diffuse | 1/50 (2.0%) | |
| Location | ||
| Frontal lobe | 22/50 (44.0%) | |
| Parietal lobe | 10/50 (20.0%) | |
| Temporal lobe | 15/50 (30.0%) | |
| Insula | 4/50 (8.0%) | |
| Basal ganglia | 4/50 (8.0%) | |
| Corpus callosum | 2/50 (4.0%) | |
| Brainstem | 7/50 (14.0%) | |
| Involvement of both cortex and subcortex | 39/50 (78.0%) | |
| Cystoid component | 28/50 (56.0%) | |
| T2‐weighted imaging signal intensity | Noncystoid component | Cystoid component |
| High intensity | 30/32 (93.8%) | 25/25 (100%) |
| Isointensity | 2/32 (6.2%) | |
| Fluid‐attenuated inversion recovery signal intensity | Noncystoid component | Cystoid component |
| High intensity | 27/29 (93.1%) | 2/16 (12.5%) |
| Isointensity | 2/29 (6.9%) | 0 |
| Low intensity | 0 | 14/16 (87.5%) |
| T1‐weighted imaging signal intensity | Noncystoid component | Cystoid component |
| High intensity | 15/40 (37.5%) | 4/28 (14.3%) |
| Isointensity | 4/40 (10.0%) | 1/28 (3.6%) |
| Low intensity | 13/40 (32.5%) | 23/28 (82.1%) |
| High and isointensity | 1/40 (2.5%) | 0 |
| High and low intensity | 5/40 (12.5%) | 0 |
| Iso‐ and low intensity | 2/40 (5.0%) | 0 |
| Intratumoral T1‐weighted imaging high‐intensity area | 23/50 (46.0%) | |
| Massive surrounding edema (≥tumor size) | 10/50 (20.0%) | |
| Stalk‐like sign | 10/50 (20.0%) | |
| Atrophy of the surrounding brain parenchyma of the tumor | 14/50 (28.0%) | |
| Contrast enhancement | ||
| Any | 11/41 (26.8%) | |
| Homogeneous | 1/41 (2.4%) | |
| Heterogeneous | 5/41 (12.2%) | |
| Nodular | 2/41 (4.9%) | |
| Rim | 2/41 (4.9%) | |
| Scarce | 1/41 (2.4%) | |
| Diffusion restriction | 1/8 (12.5%) | |
In cases where measurements in multiple directions were performed, the maximum value was used for the calculation of the tumor diameter.
FIGURE 2Brainstem angiocentric glioma in a 2‐year‐old boy presenting with right facial weakness (case 1). MRI shows a 38 × 40 × 41 mm mass in the pontomedullary region (A‐H, arrows). The tumor shows high intensity on T2‐weighted image (A) and fluid‐attenuated inversion recovery image (B), low intensity on T1‐weighted image (C) without contrast enhancement (D). T2*‐weighted image does not show intratumoral calcification or hemorrhage (E). Diffusion restriction is not observed with the mean apparent diffusion coefficient value of 1.60 × 10–3 mm2/s (F, G). Fat‐suppressed coronal T2‐weighted image shows infiltrating growth of the tumor with an ill‐defined margin (H)
FIGURE 3Supratentorial angiocentric glioma in a 43‐year‐old male presenting with refractory focal epilepsy, which started 35 years prior (case 2). MRI shows an 8 × 9 × 10 mm mass in the left frontal lobe (white arrows). The tumor contains a cystic area that is hyperintense on T2‐weighted image (A) and hypointense on fluid‐attenuated inversion recovery image (B). The stalk‐like sign (A, dotted lines) with focal atrophy of the surrounding brain parenchyma are observed on T2‐weighted coronal image. The rim of the tumor shows high intensity on precontrast enhanced T1‐weighted image (C, white arrowhead). No contrast enhancement is observed (D). Diffusion restriction is not observed with the mean apparent diffusion coefficient value of 1.04 × 10–3 mm2/s (not shown). Hematoxylin and eosin sections of the tumor demonstrate monomorphic low‐grade glial cells with an angiocentric growth pattern (E, black arrowheads; 40×) and extensive infiltration along blood vessels (F, black arrow; 10×). No calcification nor hemosiderin‐laden macrophages are observed. The main imaging features are represented in the illustration: The tumor (white arrow), the stalk‐like sign (dotted lines), focal atrophy (black arrowheads), and intratumoral T1‐weighted high intensity (white arrowhead) (G)
FIGURE 4Supratentorial angiocentric glioma in a 10‐year‐old male presenting with the first episode of epilepsy (case 3). The tumor shows high intensity on fat‐suppressed T2‐weighted image (A) and fluid‐attenuated inversion recovery image (not shown) and low intensity on T1‐weighted image (B). The stalk‐like sign is observed without evidence of atrophy in the surrounding brain parenchyma (A, dotted lines). Diffusion restriction is not observed with the mean apparent diffusion coefficient value of 1.34 × 10–3 mm2/s (D, E). Nodular enhancement is observed in the postcontrast sagittal T1‐weighted image (C, F, thick arrows)
Statistical analyses of clinical and imaging findings
| Relationship between MRI findings | Intratumoral T1WI high‐intensity area |
|
|---|---|---|
| Stalk‐like sign | ||
| Positive ( | 9/10 (90.0%) | .0031* (Fisher's exact test) |
| Negative ( | 14/40 (35.0%) | |
| Atrophy of the surrounding brain parenchyma of the tumor | ||
| Positive ( | 13/14 (92.9%) | .0001* (Fisher's exact test) |
| Negative ( | 10/36 (27.8%) | |
| Tumor location ( | Age at diagnosis (median years [range]) |
|
| Supratentorial angiocentric glioma ( | 13 [2‐83] | <.0001* (Mann‐Whitney |
| Brainstem angiocentric glioma ( | 5 [2‐7] | |
| MRI findings in patients with seizure/epilepsy history ( | Seizure/epilepsy history length (median years [range]) |
|
| Intratumoral T1WI high‐intensity area | ||
| Positive ( | 3 [<1‐35] | .0021* (Mann‐Whitney |
| Negative ( | 0.25 [<1‐10] | |
| Stalk‐like sign | ||
| Positive ( | 13.5 [<1‐35] | <.0001* (Mann‐Whitney |
| Negative ( | 1 [<1‐14] | |
| Atrophy of the surrounding brain parenchyma of the tumor | ||
| Positive ( | 14 [1‐35] | <.0001* (Mann‐Whitney |
| Negative ( | 0.5 [<1‐10] | |
Abbreviations: n, number; T1WI, T1‐weighted image.
The length was calculated by subtracting the age of seizure/epilepsy onset from age at diagnosis. Length for the patients who presented with the first episode of seizure/epilepsy was calculated as zero (n = 6). Cases without mentioning the specific history length were excluded from the calculation (n = 7).
*Statistically significant.